(Press-News.org) An international research team is the first to use artificial intelligence (AI) analysis to identify dual-purpose target candidates for the treatment of cancer and aging, the most promising of which was experimentally validated. The findings were published in the journal Aging Cell.
Researchers from the University of Oslo, University of Chicago Pritzker School of Medicine, and clinical stage AI-driven drug discovery company Insilico Medicine used Insilico’s AI target discovery engine, PandaOmics, to analyze transcriptomic data derived from 16,740 healthy samples and 11,303 tumors (across 11 solid cancers). They identified and classified a number of potential age-associated cancer targets, and validated one of most promising candidates in the simple organism Caenorhabditis elegans.
“Insilico Medicine has been working to understand the intersection of aging and disease since it was founded in 2014,” says Insilico founder and co-CEO Alex Zhavoronkov, PhD, one of the study’s authors. “With this study, we have not only identified a promising dual-purpose target for aging and disease, but validated it experimentally – which we see as an important first step in the development of dual-purpose treatments.”
Insilico Medicine’s target discovery engine, PandaOmics, draws on trillions of data points – including omics data samples (transcriptomics, genomics, epigenomics, proteomics), single cell data generated by the scientific community, compounds and biologics, patents, grants, clinical trials and publications – and analyzes that data in the context of a particular disease in order to identify actionable drug targets based on a number of key factors including novelty, confidence, commercial tractability, druggability, and safety.
In the recent study, researchers used PandaOmics to select 51 age-associated cancer targets. Of these, 22 were proposed as dual-purpose targets for an anti-aging and anti-cancer treatment with the same therapeutic direction.
Researchers next zeroed in on dual-purpose genes of interest, and found that one in particular – histone demethylase, or KDM1A – significantly extended lifespan in Caenorhabditis elegans, a simple model organism. KDM1A's anti-cancer activities have already been established in both preclinical and clinical studies, including in colorectal and triple negative breast cancers. With these latest findings, KDM1A shows promise as the first AI-identified dual-purpose target for anti-aging and anti-cancer.
“We were very encouraged by the findings,” says Evgeny Izumchenko, PfD, Assistant Professor of Medicine at UChicago in the section of hematology and oncology. “This is a first study showing the feasibility of AI-driven approaches to identify potential dual-purpose targets for anti-aging and anti-cancer treatment, and clearly demonstrates the value of such tools in addressing the complex challenges at the interface between aging and carcinogenesis.”
´We used C. elegans as a powerful aging research animal model and validated several of the AI-suggested genes as novel targets to achieve healthy aging. This is a perfect example of seamless collaborations between a basic researcher´s laboratory and an AI tycoon," says co-author Evandro F. Fang, PhD, a molecular gerontologist leading an international anti-aging laboratory at the University of Oslo, Norway.
This breakthrough follows a number of advances from Insilico Medicine in the cancer space. The Company has two AI-designed anti-cancer assets in Phase 1 trials, including a USP1 synthetic lethality inhibitor recently licensed to Exelixis for $80m upfront, and is advancing many others in its pipeline, including a recently announced highly selective covalent dual-inhibitor of CDK12/13, particularly relevant in triple negative breast cancer and pancreatic cancer.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
END
International team uses Insilico Medicine’s AI platform to find dual targets for aging and cancer
2023-11-16
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
New therapeutic strategy to reduce neuronal death in amyotrophic lateral sclerosis
2023-11-16
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects neurons in the brain and spinal cord causing loss of muscle control. A study by the University of Barcelona has designed a potential therapeutic strategy to tackle this pathology that has no treatment to date. It is a molecular trap that prevents one of the most common genetic ALS-causing peptide compounds, the Poly-GR dipeptide, from causing its toxic effects in the body. The results show that this strategy reduces the death of neurons in patients and in an animal model (vinegar flies) of the disease.
The first authors of this international research study published in the journal Science Advances are ...
Breakthrough in bladder cancer research
2023-11-16
After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of not just one, but two studies have been presented at the European Society for Medical Oncology (ESMO) conference in Madrid. The outcomes of these studies are going to revolutionize the landscape of bladder cancer treatment.
Traditionally, cisplatin-based chemotherapy has been the standard treatment for bladder cancer patients who are able to tolerate this drug. However, responses have been limited, and durable outcomes rare. Over the past years, two phase-3 clinical trials studied the effects ...
Study: Temperature variability reduces nesting success
2023-11-16
Ithaca, N.Y.—Many songbirds are nesting earlier in spring because of warmer temperatures brought about by climate change. But the shift brings another danger that is especially deadly for nestlings: greater exposure to temperature variability in the form of cold snaps and heat waves. Such extremes result in more nest failures. These findings come from a Cornell Lab of Ornithology study just published in the journal Nature Communications.
"When we talk about temperature changes, the focus is mostly on averages," said co-lead author Conor Taff, a researcher in Cornell University's ...
Understanding survival factors in critically ill patients on extracorporeal membrane oxygenation
2023-11-16
Extracorporeal membrane oxygenation (ECMO) is a widely used advanced life support procedure that provides cardiac and respiratory support to critically ill patients. ECMO use has been increasing exponentially over the last decade as it has shown success in resuscitating patients in critical situations like the COVID-19 pandemic and is now a lifesaving treatment modality in intensive care units (ICUs). However, prolonged ECMO use may be associated with an increased risk of mortality. Identifying risk factors for in-hospital mortality and developing standardized nursing practice guidelines for ECMO management may improve the survival rates in patients.
In this vein, ...
Dr. Ralph and Marian Falk Medical Research Trust awards $1.35M to two Case Western Reserve University researchers
2023-11-16
CLEVELAND—A combined $1.35 million from the Dr. Ralph and Marian Falk Medical Research Trust was awarded to two researchers from the Case Western Reserve University School of Medicine to advance their work on finding more effective treatments—and better options—for two debilitating diseases.
The Falk Trust awarded Reshmi Parameswaran, an assistant professor in the Department of Medicine, Division of Hematology/Oncology, pathology and pediatrics at the School of Medicine, $1 million over three years for her work in cancer cell therapy.
Carlos Subauste, a professor of medicine and pathology at the School of Medicine, received a two-year, ...
High levels of maternal stress during pregnancy linked to children’s behavior problems
2023-11-16
WASHINGTON – Children whose mothers are highly stressed, anxious or depressed during pregnancy may be at higher risk for mental health and behavior issues during their childhood and teen years, according to research published by the American Psychological Association.
“Our research suggests that psychological distress during the pregnancy period has a small but persistent effect on children’s risk for aggressive, disinhibited and impulsive behaviors,” said study author Irene Tung, PhD, of California State University Dominguez Hills. “These findings add to the evidence that providing widely accessible mental health care and support ...
Catalyzing clinical change: The importance of representation in health care
2023-11-16
DALLAS, November 16, 2023 — Disparities in health care persist, with Hispanic and Black adults reporting less satisfaction with their interactions with physicians, leading to poorer quality of care and health outcomes.[1],[2],[3] While 19% of people in the U.S. identify as Hispanic, fewer than 7% of physicians do.[4] This lack of representation in the delivery of health care has been shown to exacerbate health disparities among underrepresented groups and is a significant barrier to the Hispanic Latino community achieving optimal health.[5]
In response to this challenge, the American Heart Association, a global force for ...
Lithium-ion batteries are no longer the gold standard in battery tech
2023-11-16
The use of lithium metal as the anode for batteries is one of the smarter options with better energy density than other materials. However, the interface between the electrode and electrolyte has quite a few issues that can be addressed for a safer and more functional outcome in the future.
The researchers are keen on replacing the graphite anode with lithium metal anode to construct a battery system with higher energy density. However, the Li metal anode is unstable and readily reacting with electrolyte to form a solid-electrolyte interphase (SEI). Unfortunately, the natural SEI is brittle and fragile, resulting in poor ...
Gene splicing reduces effectiveness of CD20-targeting monoclonal antibodies designed to treat variety of blood cancers and disorders
2023-11-16
Philadelphia, November 16, 2023 – Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to these treatments due to a loss of the antigen that’s being targeted. Now, a new study from researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania (Penn) has found that gene splicing occurring within these cells can cause significant changes in CD20 protein levels that render the therapies ineffective.
The findings, published today by ...
IVI signs MOU with University of Cambridge, University of Hong Kong, and the Hong Kong Jockey Club to establish the Hong Kong Jockey Club Global Health Institute
2023-11-16
November 16, 2023, Republic of Korea — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, signed an MOU yesterday with University of Cambridge (UCAM), University of Hong Kong (HKU), and the Hong Kong Jockey Club (HKJC) to promote vaccine research and global health initiatives, including the establishment of the Hong Kong Jockey Club Global Health Institute (HKJCGHI).
HKJC will support the HKJCGHI through one of their largest donations in history, ...